Candel Therapeutics (CADL) Competitors $5.10 +0.11 (+2.20%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$5.10 0.00 (0.00%) As of 07/3/2025 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CADL vs. COLL, AKBA, SYRE, MLYS, AVDL, PHVS, NRIX, ARDX, ORIC, and PRAXShould you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Avadel Pharmaceuticals (AVDL), Pharvaris (PHVS), Nurix Therapeutics (NRIX), Ardelyx (ARDX), Oric Pharmaceuticals (ORIC), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. Candel Therapeutics vs. Its Competitors Collegium Pharmaceutical Akebia Therapeutics Spyre Therapeutics Mineralys Therapeutics Avadel Pharmaceuticals Pharvaris Nurix Therapeutics Ardelyx Oric Pharmaceuticals Praxis Precision Medicines Collegium Pharmaceutical (NASDAQ:COLL) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation. Is COLL or CADL more profitable? Collegium Pharmaceutical has a net margin of 6.61% compared to Candel Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 99.08% beat Candel Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Collegium Pharmaceutical6.61% 99.08% 15.14% Candel Therapeutics N/A -136.74%-63.13% Which has more risk & volatility, COLL or CADL? Collegium Pharmaceutical has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.91, meaning that its share price is 191% less volatile than the S&P 500. Do analysts prefer COLL or CADL? Collegium Pharmaceutical currently has a consensus price target of $43.75, indicating a potential upside of 44.06%. Candel Therapeutics has a consensus price target of $22.00, indicating a potential upside of 331.37%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Candel Therapeutics is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Candel Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in COLL or CADL? 13.9% of Candel Therapeutics shares are held by institutional investors. 2.5% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 16.6% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better valuation and earnings, COLL or CADL? Collegium Pharmaceutical has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCollegium Pharmaceutical$631.45M1.55$69.19M$1.2224.89Candel Therapeutics$120K2,129.25-$55.18M-$1.34-3.81 Does the media favor COLL or CADL? In the previous week, Candel Therapeutics had 7 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 14 mentions for Candel Therapeutics and 7 mentions for Collegium Pharmaceutical. Candel Therapeutics' average media sentiment score of 0.94 beat Collegium Pharmaceutical's score of 0.54 indicating that Candel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCollegium Pharmaceutical and Candel Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CADL vs. The Competition Export to ExcelMetricCandel TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$255.52M$2.92B$5.56B$9.05BDividend YieldN/A2.44%5.24%3.99%P/E Ratio-3.8121.5627.6520.23Price / Sales2,129.25283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book3.627.538.035.65Net Income-$55.18M-$55.14M$3.18B$249.15M7 Day Performance4.08%4.61%2.93%3.28%1 Month Performance-15.56%0.90%1.72%3.95%1 Year Performance-12.37%5.40%34.39%20.98% Candel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CADLCandel Therapeutics2.4715 of 5 stars$5.10+2.2%$22.00+331.4%-12.4%$255.52M$120K-3.8160Analyst RevisionCOLLCollegium Pharmaceutical4.2669 of 5 stars$29.57-1.2%$43.75+48.0%-5.6%$961.71M$631.45M24.24210News CoverageAnalyst DowngradeAKBAAkebia Therapeutics4.2524 of 5 stars$3.64-0.3%$6.75+85.4%+285.3%$958.62M$160.18M-17.33430Positive NewsInsider TradeSYRESpyre Therapeutics1.3362 of 5 stars$14.97-1.6%$53.40+256.7%-37.9%$917.39M$890K0.0073News CoverageMLYSMineralys Therapeutics2.1403 of 5 stars$13.53-1.3%$32.25+138.4%+16.9%$893.55MN/A0.0028AVDLAvadel Pharmaceuticals2.4005 of 5 stars$8.85-3.8%$18.17+105.3%-39.6%$890M$169.12M-32.7870PHVSPharvaris1.7561 of 5 stars$17.60+3.5%$36.20+105.7%+12.7%$888.93MN/A0.0030NRIXNurix Therapeutics1.6152 of 5 stars$11.39-2.1%$30.18+164.9%-34.6%$887.38M$54.55M-4.07300Trending NewsUpcoming EarningsAnalyst RevisionARDXArdelyx4.4328 of 5 stars$3.92+6.2%$10.89+177.8%-18.8%$882.85M$333.61M-17.8290ORICOric Pharmaceuticals4.2376 of 5 stars$10.15-1.6%$19.17+88.8%+40.1%$878.66MN/A-5.4380PRAXPraxis Precision Medicines2.9346 of 5 stars$42.05-2.2%$109.90+161.4%+17.2%$875.87M$8.55M0.00110Positive News Related Companies and Tools Related Companies COLL Competitors AKBA Competitors SYRE Competitors MLYS Competitors AVDL Competitors PHVS Competitors NRIX Competitors ARDX Competitors ORIC Competitors PRAX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CADL) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CADL Stock Alerts